Provided by Tiger Trade Technology Pte. Ltd.

Spruce Biosciences, Inc.

61.48
-1.9200-3.03%
Post-market: 61.480.00000.00%19:30 EDT
Volume:91.77K
Turnover:5.68M
Market Cap:176.69M
PE:-1.60
High:64.50
Open:64.50
Low:60.46
Close:63.40
52wk High:240.00
52wk Low:7.26
Shares:2.87M
Float Shares:2.29M
Volume Ratio:1.00
T/O Rate:4.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-38.4300
EPS(LYR):-50.8298
ROE:-105.98%
ROA:-40.03%
PB:2.11
PE(LYR):-1.21

Loading ...

Spruce Biosciences Inc - Collaboration Agreement With Kaken Pharmaceutical to Terminate Effective March 31, 2026 - SEC Filing

THOMSON REUTERS
·
Mar 21

Spruce Biosciences Inc - All Licenses & Rights Granted by Co to Kaken to Be Terminatde; No Unearned Milestone Payments or Royalties

THOMSON REUTERS
·
Mar 21

Spruce Biosciences FY2025 R&D expenses fell 57.97% to USD 19.5 million, net loss was USD 39 million

Reuters
·
Mar 21

Spruce Biosciences Is Maintained at Market Outperform by Citizens

Dow Jones
·
Mar 10

Spruce Biosciences Price Target Maintained With a $200.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 10

Spruce Biosciences price target lowered to $170 from $180 at Citizens

TIPRANKS
·
Mar 10

Rpt-Spruce Biosciences FY Net Income USD -38.966 Million

THOMSON REUTERS
·
Mar 09

Spruce Biosciences Inc - to Offer and Sell Common Stock up to $75 Mln Through Jefferies - SEC Filing

THOMSON REUTERS
·
Mar 09

Spruce Biosciences Inc - May Offer and Sell Common Stock up to Maximum Program Amount Under Sales Agreement - SEC Filing

THOMSON REUTERS
·
Mar 09

Spruce Biosciences Inc - Enters Open Market Sale Agreement With Jefferies Llc on March 9, 2026 - SEC Filing

THOMSON REUTERS
·
Mar 09

BRIEF-Spruce Biosciences Reports Full Year 2025 Financial Results

Reuters
·
Mar 09

Spruce Biosciences 2025 net loss narrows, secures $50 mln funding

Reuters
·
Mar 09

Spruce Biosciences FY 2025 R&D expenses fall 58% to USD 19.52 million, net loss narrows 27% to USD 38.97 million

Reuters
·
Mar 09

Spruce Biosciences Inc - Expects Cash and Cash Equivalents to Fund Current Operating Plan Into Early 2027

THOMSON REUTERS
·
Mar 09

Spruce Biosciences Inc - Bla Submission for Ta-Ert for Treatment of Sanfilippo Syndrome Type B (Mps Iiib) on Track for Q4 2026

THOMSON REUTERS
·
Mar 09

Spruce Biosciences Inc - Net Loss $39.0 Mln for Year Ended Dec 31, 2025

THOMSON REUTERS
·
Mar 09

Press Release: Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Dow Jones
·
Mar 09

Spruce Biosciences names Dale Hooks chief commercial officer

Reuters
·
Mar 09

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

THOMSON REUTERS
·
Mar 09

Spruce Biosciences CEO Javier Szwarcberg to Present at Leerink Global Healthcare Conference and The Citizens Life Sciences Conference

Reuters
·
Mar 03